Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig A Bunnell

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 3, 2012
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsLinda T Vahdat, Eva S Thomas, Henri H Roché, et al.
Breast (Edinburgh, Scotland)|October 11, 2016
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective studyRomualdo Barroso-Sousa, Flavia Rocha Paes, Ines Vaz-Luis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerEva Thomas, Josep Tabernero, Monica Fornier, et al.
JCO Oncology Practice|May 16, 2023
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and ReimbursementDario Trapani, Qingchun Jin, Caroline C Block, et al.
International Journal of Radiation Oncology, Biology, Physics|October 26, 2005
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancerHarold J Burstein, Jennifer R Bellon, Sharon Galper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapyHarold J Burstein, Leroy M Parker, Aparna Keshaviah, et al.
BMJ Quality & Safety|January 26, 2013
High performance teamwork training and systems redesign in outpatient oncologyCraig A Bunnell, Anne H Gross, Saul N Weingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithmHarold J Burstein, Lyndsay N Harris, P Kelly Marcom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot studyHarold J Burstein, Lyndsay N Harris, Rebecca Gelman, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 3, 2012
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsLinda T Vahdat, Eva S Thomas, Henri H Roché, et al.
Breast (Edinburgh, Scotland)|October 11, 2016
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective studyRomualdo Barroso-Sousa, Flavia Rocha Paes, Ines Vaz-Luis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerEva Thomas, Josep Tabernero, Monica Fornier, et al.
JCO Oncology Practice|May 16, 2023
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and ReimbursementDario Trapani, Qingchun Jin, Caroline C Block, et al.
International Journal of Radiation Oncology, Biology, Physics|October 26, 2005
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancerHarold J Burstein, Jennifer R Bellon, Sharon Galper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapyHarold J Burstein, Leroy M Parker, Aparna Keshaviah, et al.
BMJ Quality & Safety|January 26, 2013
High performance teamwork training and systems redesign in outpatient oncologyCraig A Bunnell, Anne H Gross, Saul N Weingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithmHarold J Burstein, Lyndsay N Harris, P Kelly Marcom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot studyHarold J Burstein, Lyndsay N Harris, Rebecca Gelman, et al.
Pageof 3